Who are Retaine™'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): carboxymethylcellulose 0.5% +glycerin 0.9%, Hylo-comod, Sodium Hyaluronate Ophthalmic 0.4%, Blink tears, REFRESH LIQUIGEL®, preservative-free 0.15% HA.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/retaine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Retaine™ — Competitive Intelligence Brief

Retaine™ (Retaine™) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Artificial tear / ocular lubricant. Area: Ophthalmology.

marketed Artificial tear / ocular lubricant Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Retaine™ (Retaine™) — Ocusoft, Inc.. Retaine is an ophthalmic emulsion that lubricates and protects the ocular surface by supplementing natural tears and reducing evaporation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Retaine™ TARGET	Retaine™	Ocusoft, Inc.	marketed	Artificial tear / ocular lubricant
carboxymethylcellulose 0.5% +glycerin 0.9%	carboxymethylcellulose 0.5% +glycerin 0.9%	Allergan	marketed	Artificial tear / ocular lubricant
Hylo-comod	Hylo-comod	Oslo University Hospital	marketed	Artificial tear / Ocular lubricant	Ocular surface (non-receptor mediated)
Sodium Hyaluronate Ophthalmic 0.4%	Sodium Hyaluronate Ophthalmic 0.4%	Laboratorios Sophia S.A de C.V.	marketed	Artificial tear / Ocular lubricant
Blink tears	Blink tears	Medical University of South Carolina	marketed	Artificial tear / Ocular lubricant
REFRESH LIQUIGEL®	REFRESH LIQUIGEL®	Allergan	marketed	Artificial tear / ocular lubricant
preservative-free 0.15% HA	preservative-free 0.15% HA	Chang Gung Memorial Hospital	marketed	Artificial tear / ocular lubricant

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Artificial tear / ocular lubricant class)

Allergan · 2 drugs in this class
Chang Gung Memorial Hospital · 1 drug in this class
Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 1 drug in this class
Medical University of Vienna · 1 drug in this class
Nguyen Viet Giap · 1 drug in this class
ORA, Inc. · 1 drug in this class
Ocusoft, Inc. · 1 drug in this class
The Mentholatum Company · 1 drug in this class
Tianjin Eye Hospital · 1 drug in this class
University of Sao Paulo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Retaine™ — Competitive Intelligence Brief. https://druglandscape.com/ci/retaine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab